FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283735086> ?p ?o ?g. }

• W4283735086 abstract "Background and purpose: The COVID-19 pandemic continues to pose challenges, especially with the emergence of new SARS-CoV-2 variants that are associated with higher infectivity and/or compromised protection afforded by the current vaccines. There is a high demand for additional preventive and therapeutic strategies effective against this changing virus. Repurposing of approved or clinically tested drugs can provide an immediate solution. Experimental Approach: We applied a novel computational approach to search among approved and commercially available drugs. Antiviral activity of a predicted drug, azelastine, was tested in vitro in SARS-CoV-2 infection assays with Vero E6 cells, Vero cells stably overexpressing the human TMPRSS2 and ACE2 proteins as well as on reconstituted human nasal tissue using the predominant variant circulating in Europe in summer 2020, B.1.177 (D614G variant), and its emerging variants of concern; B.1.1.7 (alpha), B.1.351 (beta) and B.1.617.2 (delta) variants. The effect of azelastine on viral replication was assessed by quantification of viral genomes by droplet digital PCR or qPCR. Key results: The computational approach identified major drug families, such as anti-infective, anti-inflammatory, anti-hypertensive, antihistamine, and neuroactive drugs. Based on its attractive safety profile and availability in nasal formulation, azelastine, a histamine 1 receptor-blocker was selected for experimental testing. Azelastine reduced the virus-induced cytopathic effect and SARS-CoV-2 copy numbers both in preventive and treatment settings upon infection of Vero cells with an EC50 of 2.2-6.5 µM. Comparable potency was observed with the alpha, beta and delta variants. Furthermore, five-fold dilution (containing 0.02% azelastine) of the commercially available nasal spray formulation was highly potent in inhibiting viral propagation in reconstituted human nasal tissue. Conclusion and Implications: Azelastine, an antihistamine available as nasal sprays developed against allergic rhinitis may be considered as a topical prevention or treatment of nasal colonization by SARS-CoV-2. A Phase 2 efficacy indicator study with azelastine-containing nasal spray that was designed based on the findings reported here has been concluded recently, confirming accelerated viral clearance in SARS-CoV-2 positive subjects." @default.
• W4283735086 created "2022-07-01" @default.
• W4283735086 creator A5000276878 @default.
• W4283735086 creator A5007494581 @default.
• W4283735086 creator A5020407813 @default.
• W4283735086 creator A5031739659 @default.
• W4283735086 creator A5031984206 @default.
• W4283735086 creator A5038442611 @default.
• W4283735086 creator A5049682751 @default.
• W4283735086 creator A5052971511 @default.
• W4283735086 creator A5053347767 @default.
• W4283735086 creator A5054395879 @default.
• W4283735086 creator A5062127452 @default.
• W4283735086 creator A5066205556 @default.
• W4283735086 creator A5077702058 @default.
• W4283735086 creator A5086282112 @default.
• W4283735086 creator A5089710020 @default.
• W4283735086 date "2022-06-30" @default.
• W4283735086 modified "2023-10-16" @default.
• W4283735086 title "The Anti-Histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits Infection by Major Variants of SARS-CoV-2 in Cell Cultures and Reconstituted Human Nasal Tissue" @default.
• W4283735086 cites W1977306693 @default.
• W4283735086 cites W2075689919 @default.
• W4283735086 cites W2076911722 @default.
• W4283735086 cites W2357951426 @default.
• W4283735086 cites W2597115993 @default.
• W4283735086 cites W2896002881 @default.
• W4283735086 cites W2933138968 @default.
• W4283735086 cites W2989298339 @default.
• W4283735086 cites W3009456922 @default.
• W4283735086 cites W3009577418 @default.
• W4283735086 cites W3009914955 @default.
• W4283735086 cites W3011072970 @default.
• W4283735086 cites W3013359483 @default.
• W4283735086 cites W3015353977 @default.
• W4283735086 cites W3017214219 @default.
• W4283735086 cites W3022285953 @default.
• W4283735086 cites W3023724901 @default.
• W4283735086 cites W3033905495 @default.
• W4283735086 cites W3044059177 @default.
• W4283735086 cites W3044416430 @default.
• W4283735086 cites W3044927477 @default.
• W4283735086 cites W3047903801 @default.
• W4283735086 cites W3082160025 @default.
• W4283735086 cites W3094560806 @default.
• W4283735086 cites W3097146219 @default.
• W4283735086 cites W3101087608 @default.
• W4283735086 cites W3109172892 @default.
• W4283735086 cites W3114250596 @default.
• W4283735086 cites W3122083218 @default.
• W4283735086 cites W3137359073 @default.
• W4283735086 cites W3156990363 @default.
• W4283735086 cites W3158868742 @default.
• W4283735086 cites W3161198291 @default.
• W4283735086 cites W3165331948 @default.
• W4283735086 cites W3173547614 @default.
• W4283735086 cites W3184265660 @default.
• W4283735086 cites W3189646261 @default.
• W4283735086 cites W3193526107 @default.
• W4283735086 cites W3203278173 @default.
• W4283735086 cites W3204035386 @default.
• W4283735086 cites W3209421898 @default.
• W4283735086 cites W3210016516 @default.
• W4283735086 cites W4200414711 @default.
• W4283735086 cites W4220814154 @default.
• W4283735086 doi "https://doi.org/10.3389/fphar.2022.861295" @default.
• W4283735086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35846988" @default.
• W4283735086 hasPublicationYear "2022" @default.
• W4283735086 type Work @default.
• W4283735086 citedByCount "9" @default.
• W4283735086 countsByYear W42837350862021 @default.
• W4283735086 countsByYear W42837350862022 @default.
• W4283735086 countsByYear W42837350862023 @default.
• W4283735086 crossrefType "journal-article" @default.
• W4283735086 hasAuthorship W4283735086A5000276878 @default.
• W4283735086 hasAuthorship W4283735086A5007494581 @default.
• W4283735086 hasAuthorship W4283735086A5020407813 @default.
• W4283735086 hasAuthorship W4283735086A5031739659 @default.
• W4283735086 hasAuthorship W4283735086A5031984206 @default.
• W4283735086 hasAuthorship W4283735086A5038442611 @default.
• W4283735086 hasAuthorship W4283735086A5049682751 @default.
• W4283735086 hasAuthorship W4283735086A5052971511 @default.
• W4283735086 hasAuthorship W4283735086A5053347767 @default.
• W4283735086 hasAuthorship W4283735086A5054395879 @default.
• W4283735086 hasAuthorship W4283735086A5062127452 @default.
• W4283735086 hasAuthorship W4283735086A5066205556 @default.
• W4283735086 hasAuthorship W4283735086A5077702058 @default.
• W4283735086 hasAuthorship W4283735086A5086282112 @default.
• W4283735086 hasAuthorship W4283735086A5089710020 @default.
• W4283735086 hasBestOaLocation W42837350861 @default.
• W4283735086 hasConcept C103637391 @default.
• W4283735086 hasConcept C1122143 @default.
• W4283735086 hasConcept C126322002 @default.
• W4283735086 hasConcept C140704245 @default.
• W4283735086 hasConcept C159047783 @default.
• W4283735086 hasConcept C159545944 @default.
• W4283735086 hasConcept C170493617 @default.
• W4283735086 hasConcept C203014093 @default.
• W4283735086 hasConcept C2522874641 @default.
• W4283735086 hasConcept C2776885963 @default.
• W4283735086 hasConcept C2780035454 @default.

• next